Page 4 - Developing Drugs News Today

WASHINGTON, D.C. – Reps. Mike Gallagher (R-WI), Anna G. Eshoo (D-CA), Brett Guthrie (R-KY), Jan Schakowsky (D-IL), Gus Bilirakis (R-FL), Mike Quigley (D-IL),

Zynerba Pharmaceuticals (ZYNE) stock rose ~8% premarket June 22 after the company said its transdermal CBD gel Zygel help improve behavior symptoms of 22q11.2 Deletion Syndrome in...

Novocure (NVCR) and Zai Lab (ZLAB) said a mid-stage study of their investigational device for Tumor Treating Fields (TTFields) met its main goal in patients with gastric...

Merck KGaA's (MKGAF) (MKKGY) will spend ~€440M to expand its membrane and filtration manufacturing capabilities in Ireland.The German company said the investment, which is the largest in...

Concert Pharmaceuticals (CNCE) said a phase 3 trial of its oral drug CTP-543 met the main goal of scalp hair regrowth at both doses in patients with with moderate to severe...

Tricida (TCDA) said it is stopping its VALOR-CKD trial of veverimer for kidney disease early due to administrative reasons pursuant to a study protocol to allow for six months of...

This cohort study evaluates the association of COVID-19 infection with olfactory bulb by performing an ultrastructural and histopathological analysis of patient

Citius Pharmaceuticals (CTXR) said a phase 3 trial of its drug I/ONTAK, a new formulation of a discontinued drug  ONTAK, showed the therapy to be consistent with the prior formulation...

Share: NEW YORK, July 18, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, presented 90-day survival outcomes from the 222-patient randomized controlled trial of remestemcel-L in ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS) at an invited presentation on July 17 to the International Society for Cell & Gene Therapy (ISCT) Scientific Signatures Se...

To embed, copy and paste the code into your website or blog: Welcome to our monthly roundup of regulatory and litigation highlights impacting the dietary supplement and personal care products industries.  Sit back, relax, and enjoy the read.  February was a short month, with a lot going on. NAD Health claim substantiation was front and center before NAD in a monitoring case involving Pendulum Therapeutics and a “medical probiotic” product featuring claims such as “The only medical probi...